John Newman is ranked #2387 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

John Newman (Canaccord Genuity) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are John Newman's stock ratings?

About 43% of John's ratings were profitable over a one-year hold, with an average return of -8.9% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/John Newman

John Newman

Canaccord Genuity

Wall Street Analyst

★☆☆☆☆

#2387

on 13Foresight · ranked by our own returns

43%

Success Rate

-9.0%

Average Return

26 of 60 calls profitable · -11362.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 43% of John Newman's ratings turned a profit when each position was held for 1 year — averaging -9.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

149 Buy 8 Hold 0 Sell

John's Stock Coverage 49 ratings · 2026-07-15

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ACET Adicet Bio	Jul 13, 2026	BUY	Strong Buy +186.7% avg upside 14 analysts	$18.00 103.86% Upside	·
DCTH Delcath Systems	Jul 10, 2026	BUY	Strong Buy +64.8% avg upside 11 analysts	$21.00 59.87% Upside	-1.1%
TYRA Tyra Bioscience	Jul 09, 2026	BUY	Strong Buy +35.9% avg upside 17 analysts	$50.00 51.98% Upside	-1.0%
MCRB Seres Therapeutics	Jul 09, 2026	BUY	Buy +209.3% avg upside 11 analysts	$22.00 312.42% Upside	·
BBOT BridgeBio Oncology Therapeutics	Jul 08, 2026	BUY	Strong Buy +188.1% avg upside 10 analysts	$23.00 160.81% Upside	+0.0%
CMPX Compass Therapeutics	Jul 01, 2026	BUY	Strong Buy +335.2% avg upside 19 analysts	$7.00 219.68% Upside	+4.4%
TNGX Tango Therapeutics	Jun 29, 2026	BUY	Strong Buy +28.3% avg upside 14 analysts	$46.00 55.21% Upside	-11.2%
MRKR Marker Therapeutics	Jun 29, 2026	BUY	Strong Buy +904.8% avg upside 9 analysts	$8.00 455.56% Upside	+3.4%
NUVL Nuvalent	Jun 10, 2026	HOLD	Buy -0.7% avg upside 21 analysts	$126.00 1.59% Upside	+0.4%
BNTX BioNTech SE	Jun 01, 2026	BUY	Strong Buy +51.1% avg upside 26 analysts	$158.00 74.83% Upside	-0.2%
REGN Regeneron	May 19, 2026	BUY	Strong Buy +17.3% avg upside 58 analysts	$875.00 33.30% Upside	+4.2%
CADL Candel Therapeutics	May 18, 2026	BUY	Strong Buy +82.8% avg upside 11 analysts	$25.00 153.33% Upside	+24.4%
ALLO Allogene Therapeutics	May 14, 2026	BUY	Strong Buy +716.4% avg upside 28 analysts	$14.00 656.66% Upside	-11.2%
ATRA Atara Biotherapeutics	May 13, 2026	BUY	Buy +120.3% avg upside 18 analysts	$13.00 61.63% Upside	-7.7%
LCTX Lineage Therap	May 13, 2026	BUY	Strong Buy +339.3% avg upside 16 analysts	$9.00 637.74% Upside	-4.7%
XNCR Xencor	May 06, 2026	BUY	Strong Buy +119.7% avg upside 27 analysts	$38.00 154.14% Upside	-13.4%
IRD Opus Genetics	Nov 12, 2024	BUY	Strong Buy +189.2% avg upside 24 analysts	$10.00 180.81% Upside	+68.4%
ONCY Oncolytics Biotech	Nov 12, 2024	BUY	Strong Buy +691.1% avg upside 12 analysts	$5.00 450.46% Upside	+1.8%
PTN Palatin Technologies	Oct 01, 2024	BUY	Strong Buy +1223.9% avg upside 4 analysts	$300.00 3289.84% Upside	-82.2%
RNAC Cartesian Therapeutics	Aug 08, 2024	BUY	Strong Buy +265.4% avg upside 19 analysts	$43.00 398.84% Upside	-18.2%
AGIO Agios Pharma	Feb 16, 2022	BUY	Buy +51.5% avg upside 29 analysts	$44.00 10.15% Upside	-12.7%
CARM Carisma Therapeutics	Aug 17, 2021	BUY	Buy +56150.0% avg upside 11 analysts	$3.00 57592.22% Upside	·
HK:0013 HUTCHMED (China)	May 26, 2021	BUY	Buy +548.6% avg upside 6 analysts	$352.68 1806.42% Upside	·
BDSX Biodesix	May 12, 2021	BUY	Strong Buy +52.3% avg upside 8 analysts	$31.00 46.78% Upside	-87.7%
KLDO Kaleido Biosciences	May 04, 2021	BUY	Buy +13249900.0% avg upside 5 analysts	$19.00 18999900.00% Upside	-98.9%
HCM HUTCHMED	May 03, 2021	BUY	Strong Buy +179.3% avg upside 9 analysts	$45.00 299.95% Upside	-53.4%
RNTX Rein Therapeutics	Mar 25, 2021	BUY	Strong Buy +1064.8% avg upside 5 analysts	$5.00 445.94% Upside	-61.5%
TSE:PRN Profound Medical	Mar 09, 2020	BUY	Strong Buy +88.5% avg upside 11 analysts	$14.05 40.67% Upside	·
ALDX Aldeyra Therapeutics	Jun 26, 2019	BUY	Strong Buy +721.8% avg upside 21 analysts	$20.00 936.33% Upside	-31.0%
MTVA MetaVia	Aug 13, 2018	BUY	Strong Buy +1465.3% avg upside 13 analysts	$6.00 210.96% Upside	-61.5%
XENE Xenon	Jun 27, 2017	BUY	Strong Buy -6.5% avg upside 28 analysts	$5.00 92.47% Downside	·
AUPH Aurinia Pharmaceuticals	Mar 10, 2017	BUY	Strong Buy -4.8% avg upside 12 analysts	$10.00 37.48% Downside	-34.8%
CBIO Crescent Biopharma	Mar 01, 2017	BUY	Strong Buy +46.5% avg upside 17 analysts	$12.00 21.64% Downside	·
IMUX Immunic	Dec 30, 2016	BUY	Strong Buy +152.9% avg upside 21 analysts	$10.00 31.85% Downside	+36.8%
DARE Daré Bioscience	Nov 09, 2016	BUY	Strong Buy +542.6% avg upside 14 analysts	$60.00 2798.53% Upside	-65.2%
LPCN Lipocine	Oct 11, 2016	BUY	Strong Buy +679.2% avg upside 4 analysts	$15.00 549.29% Upside	-19.7%
ZVRA Zevra Therapeutics	Aug 10, 2016	BUY	Strong Buy +82.4% avg upside 15 analysts	$34.00 160.35% Upside	-20.6%
SVRA Savara	Jul 26, 2016	BUY	Strong Buy +52.3% avg upside 17 analysts	$3.00 47.30% Downside	-32.4%
GEO Geo Group	Jun 13, 2016	HOLD	Strong Buy +22.9% avg upside 11 analysts	$90.00 202.18% Upside	+54.8%
RCKT Rocket Pharmaceuticals	May 13, 2016	BUY	Buy +350.8% avg upside 29 analysts	$30.00 724.23% Upside	-81.8%
ZG Zillow Group Class A	May 02, 2016	BUY	Buy +99.4% avg upside 45 analysts	$26.00 18.21% Downside	+51.2%
MU Micron	Mar 31, 2016	BUY	Strong Buy -0.1% avg upside 53 analysts	$18.00 98.14% Downside	+176.0%
TLPH Talphera	Mar 09, 2015	HOLD	Strong Buy +236.1% avg upside 15 analysts	$6.00 327.07% Upside	-34.7%
JAZZ Jazz Pharmaceuticals	Mar 03, 2015	BUY	Strong Buy -7.0% avg upside 35 analysts	$201.00 15.48% Downside	-28.8%
RMTI Rockwell Med	Jan 07, 2015	BUY	Hold +111.0% avg upside 11 analysts	$24.00 326.23% Upside	-20.8%
ARCT Arcturus Therapeutics	Oct 07, 2014	HOLD	Buy +354.1% avg upside 36 analysts	$9.00 41.22% Upside	-9.2%
BIIB Biogen	Dec 20, 2011	BUY	Strong Buy +27.2% avg upside 52 analysts	$127.00 33.80% Downside	+36.6%
MNKD MannKind	Mar 15, 2010	SELL	Buy +80.0% avg upside 22 analysts	$5.00 28.81% Upside	+52.0%
BC Brunswick	Jun 10, 2009	SELL	Buy +5.0% avg upside 32 analysts	—	-273.8%

🔒 44 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

John Newman — Frequently Asked Questions

How accurate are John Newman's stock ratings?

Based on the calls 13Foresight could measure, about 43% of John's ratings were profitable over a one-year hold, with an average return of -8.9% per rating, or -11362.6% versus the S&P 500. We score every analyst the same way, from historical prices.

How is John ranked on 13Foresight?

John Newman is currently ranked #2387 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does John cover?

John most recently has ratings on ACET, DCTH, TYRA, MCRB, BBOT, CMPX, TNGX, MRKR, NUVL, BNTX, REGN, CADL and 37 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!